



17 March 2020

The Best of Both Worlds

Cystic Fibrosis Australia (CFA) is thrilled to announce that Pharmaxis and For Benefits Medicine (FBM) will collaborate to provide CF clinic support and more funding for Australian Cystic Fibrosis Research (ACFRT).

Pharmaxis, the Australian manufacturer of Bronchitol[®], is now able to provide field based support to CF treating teams and drive more funding for CF research in Australia through a partnership with For Benefit Medicines.

For Benefit Medicines is an Australian company pioneering the concept that all profits generated from the sale of a registered product can be donated to fund medical research and patient support in that therapeutic area. FBM currently has products in various therapeutic areas including cystic fibrosis (CF) and cancer.

From March 2020, FBM will be responsible for Australian CF clinic liaison and support for both Tobramycin and Bronchitol[®] (mannitol). Any profits made by FBM from the sale of these two products in Australia will be donated to Cystic Fibrosis Australia to fund local medical research.

Gary Phillips, Pharmaxis CEO commented, "As an Australian organisation focused on research and new drug development in areas of high unmet need, Pharmaxis is delighted to be able to partner with FBM, another local company committed to driving Australian research. This partnership will allow Pharmaxis to provide in-field support for Bronchitol which will benefit CF clinics and their patients".

FBM directors John Hurley and Dr Barry Frost said, "We are excited to be able to drive further funding for Australian CF research by having a second CF product in our portfolio. Antibiotics and mucus clearance are important treatments for people living with CF, so this partnership allows further benefits to patients via the provision of quality products, and direct funding to local research through the ACFRT".

Cystic Fibrosis Australia is thrilled to see Australian companies putting patients before profits. It is great to see FBM and Pharmaxis finding ways to put real money back into local research that will benefit the Australian CF community.

The quality of CF research generated in Australia is very high and we are all excited that more funding will be available from the sale of these products to improve the lives of people with CF.

Kind regards

Nettie Burke
CEO
Cystic Fibrosis Australia